Handelsbanken Fonder
RCKT icon

Handelsbanken Fonder’s Rocket Pharmaceuticals RCKT Stock Holding History

Handelsbanken Fonder’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-23,100
Closed -$154K – 1560
2025
Q1 		$154K Hold
23,100
– – ﹤0.01% 1504
2024
Q4 		$290K Buy
23,100
+4,900
+27% +$73.8K ﹤0.01% 1459
2024
Q3 		$336K Hold
18,200
– – ﹤0.01% 1384
2024
Q2 		$392K Buy
18,200
+600
+3% +$13.8K ﹤0.01% 1271
2024
Q1 		$474K Hold
17,600
– – ﹤0.01% 1187
2023
Q4 		$527K Buy
17,600
+5,300
+43% +$117K ﹤0.01% 1122
2023
Q3 		$252K Hold
12,300
– – ﹤0.01% 1373
2023
Q2 		$244K Buy
+12,300
New +$249K ﹤0.01% 1432
2022
Q1 		– Sell
-9,600
Closed -$210K – 1724
2021
Q4 		$210K Hold
9,600
– – ﹤0.01% 1695
2021
Q3 		$287K Hold
9,600
– – ﹤0.01% 1600
2021
Q2 		$425K Buy
9,600
+4,000
+71% +$174K ﹤0.01% 1492
2021
Q1 		$248K Buy
+5,600
New +$307K ﹤0.01% 1495

Other funds holding RCKT

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return

Handelsbanken Fonder's RCKT Position: Q2 2025 in Review

Handelsbanken Fonder sold out of Rocket Pharmaceuticals (RCKT) in Q2 2025, closing a stake of 23,100 shares — an estimated $154K sold.

Handelsbanken Fonder first reported a position in RCKT in Q1 2021 and held it in 12 quarters. The position peaked at $527K in Q4 2023. 196 funds tracked by Wall St. Rank hold RCKT as of Q2 2025.

  • Handelsbanken Fonder reported no remaining Rocket Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Handelsbanken Fonder sold 23,100 Rocket Pharmaceuticals shares in Q2 2025, an estimated $154K.
  • Handelsbanken Fonder first reported a position in Rocket Pharmaceuticals in Q1 2021 and held it in 12 quarters.
  • Handelsbanken Fonder's Rocket Pharmaceuticals position peaked at $527K in Q4 2023.
  • 196 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2025.

Based on Handelsbanken Fonder's 13F filing for Q2 2025, filed 12 Aug 2025.